Headache is one of the most prevalent disorders of the nervous system. Headache is also the most common symptom of a variety of diseases, including migraine, Covid-19. International
Classification of Headache Disorders (ICHD) lists over a thousand different types of headaches. Migraine is a widely known type of primary headache. Much research supports
that the enhancement in migraine intensity related to chronic migraine such as neurogenic
neuroinflammation, possibly leading to increased cytokine expression via activation of protein kinases in neurons and glial cells of the trigeminovascular system like some of the other headache diseases (1). No currently drug class available, either specific (triptans, ergots) or non-specific (opioids, paracetamol, NSAIDs), is effective in all types of headaches, in all patients and all attacks of the same patient. However, non-steroidal anti-inflammatory drugs (NSAIDs) minimize prostaglandin synthesis by blocking cyclooxygenase, which is included in the pathophysiology of migraine headaches. We searched the employed source was The Journal of Headache and Pain database by using NSAIDs with Headache, Migraine, and Covid-19 keywords. The search was performed from April 2021 and included 2017-2018-2019-2020-2021 (last five years) the studies and reviews from the Journal of Headache and Face Pain Sites. Additionally, we noted the published or on-going studies, 8 of these, about NSAIDs information contain searches that exist in the 12th European Headache Federation Congress (jointly with 32nd National Congress of the Italian Society) Study of Headaches’ book (2). And also, we included relationship migraine with Covid-19 studies to highlight the connection between the headache, which is one of the most common symptoms of both migraine and Covid-19, and the importance of managing migraine pain with NSAIDs during corona processing.
Headache Migraine Neuroinflammation Non-steroid Anti-inflammatory drugs (NSAIDs)
Birincil Dil | İngilizce |
---|---|
Konular | Sağlık Kurumları Yönetimi |
Bölüm | Clinical Research |
Yazarlar | |
Yayımlanma Tarihi | 9 Ekim 2021 |
Gönderilme Tarihi | 10 Nisan 2021 |
Kabul Tarihi | 23 Nisan 2021 |
Yayımlandığı Sayı | Yıl 2021 Cilt: 38 Sayı: 4 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.